Page last updated: 2024-09-02
exp3174 and embusartan
exp3174 has been researched along with embusartan in 1 studies
Compound Research Comparison
| Studies (exp3174) | Trials (exp3174) | Recent Studies (post-2010) (exp3174) | Studies (embusartan) | Trials (embusartan) | Recent Studies (post-2010) (embusartan) |
|---|---|---|---|---|---|
| 236 | 29 | 43 | 8 | 1 | 0 |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Iouzalen, L; Marche, P; Stepien, O | 1 |
Other Studies
1 other study(ies) available for exp3174 and embusartan
| Article | Year |
|---|---|
Effects of BAY 10-6734 (Embusartan), a new angiotensin II type I receptor antagonist, on vascular smooth muscle cell growth.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Calcium; Cell Division; Cells, Cultured; Cytosol; Dihydropyridines; DNA; Imidazoles; Losartan; Male; Muscle, Smooth, Vascular; Protein Biosynthesis; Radioligand Assay; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Species Specificity; Tetrazoles | 1999 |